Rein Therapeutics (RNTX) EBITDA (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly EBITDA of -$5.2 million for Q1 2026, up 6.76% year-over-year from -$4.9 million in Q1 2025, and up 83.99% quarter-over-quarter from -$32.7 million in Q4 2025.
Rein Therapeutics (RNTX) EBITDA (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported EBITDA for 11 consecutive years, with -$5.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 6.76% year-over-year to -$5.2 million; the TTM figure through Mar 2026 stood at -$50.3 million (up 20.88% YoY), while the FY2025 annual figure was -$50.6 million, up 22.24% from the prior year.
- EBITDA grew to -$5.2 million in Q1 2026 per RNTX's latest filing, from -$32.7 million in the prior quarter.
- Across five years, EBITDA topped out at -$2.0 million in Q3 2023 and bottomed at -$42.8 million in Q4 2024.
- Historically, EBITDA has averaged -$9.7 million across 5 years, with a median of -$6.5 million in 2022.
- Annual changes were most pronounced in 2023 — EBITDA jumped 75.23% — and 2024, when it tumbled 487.06%.
- Rein Therapeutics' EBITDA stood at -$4.7 million in 2022, then tumbled by 55.01% to -$7.3 million in 2023, then sank by 487.06% to -$42.8 million in 2024, then gained by 23.69% to -$32.7 million in 2025, then soared by 83.99% to -$5.2 million in 2026.
- Business Quant data shows RNTX's EBITDA at -$5.2 million in Q1 2026, -$32.7 million in Q4 2025, and -$5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 133.12 Mn |
| 10 | Rein Therapeutics | 56.18 Mn | 56.18 Mn | - | -6.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.08 Mn |
| Mar 31, 2026 | -5.23 Mn |
| Dec 31, 2025 | -32.66 Mn |
| Sep 30, 2025 | -5.49 Mn |
| Jun 30, 2025 | -6.87 Mn |
| Mar 31, 2025 | -5.61 Mn |
| Dec 31, 2024 | -42.80 Mn |
| Sep 30, 2024 | -6.07 Mn |
| Jun 30, 2024 | -9.04 Mn |
| Mar 31, 2024 | -7.21 Mn |
| Dec 31, 2023 | -7.29 Mn |
| Sep 30, 2023 | -1.98 Mn |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | -5.01 Mn |
| Dec 31, 2022 | -4.70 Mn |
| Sep 30, 2022 | -6.48 Mn |
| Jun 30, 2022 | -8.04 Mn |
| Mar 31, 2022 | -8.42 Mn |
| Dec 31, 2021 | -6.82 Mn |
| Sep 30, 2021 | -6.79 Mn |